Navarrete-Reyes AP, Ávila-Funes JA

Idioma: Español
Referencias bibliográficas: 31
Paginas: 327-332
Archivo PDF: 62.72 Kb.

RESUMEN

Frecuentemente los grandes síndromes geriátricos se presentan en pacientes con multipatología; tal vez el ejemplo más evidente sea la diabetes mellitus (DM). Durante los últimos años se ha evidenciado una asociación entre la presencia de DM y el fenotipo de fragilidad en los ancianos. En el contexto teórico, existen múltiples vías que justifican tal asociación, sobre todo en la DM2 de larga evolución. Sin embargo, hay también datos que sugieren una relación de diferente índole entre el fenotipo de fragilidad y la DM que ha iniciado durante la vejez. Este artículo tiene como fin el revisar la evidencia actual acerca de la interacción entre DM y fragilidad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rodríguez-Saldana J, Morley JE, Reynoso MT, et al. Diabetes mellitus in a subgroup of older Mexicans: prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc 2002; 50; 111-16.

2. Kim MJ, Rolland Y, Cepeda O, et al. Diabetes mellitus in older men. Aging Male 2006; 9: 139-47.

3. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-M156.

4. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55; M716-M724.

5. Morley JE, Haren MT, Rolland Y et al. Frailty. Med Clin North Am 2006; 90; 837-47.

6. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92; 4241-7.

7. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23; 490-4.

8. Laaksonen DE, Niskanen L, Punnonen K et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27; 1036-41.

9. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003; 58; M1103-M1110.

10. Sattler FR, Castaneda-Sceppa C, Binder EF, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009; 94; 1991-2001.

11. Morley JE, Kim MJ, Haren MT. Frailty and hormones. Rev Endocr Metab Disord 2005;6,101-08.

12. Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syndrome. Am J Med 2007;120: 748-53.

13. Walston J, McBurnie MA, Newman A et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 2333-41.

14. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med 2009; 122: 605-13.

15. Schwartz AV, Hillier TA, Sellmeyer, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749-54.

16. Volpato S, Leveille SG, Blaum C, et al. Risk factors for falls in older disabled women with diabetes: the women’s health and aging study. J Gerontol A Biol Sci Med Sci 2005; 60: 1539-45.

17. Ivers RQ, Cumming RG, Mitchell P et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001; 24: 1198-203.

18. Levine JP. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 2006; 8: 40-53.

19. Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008; 22: 765-85.

20. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med 2009; 122: 793-802.

21. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC. et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999-2006.

22. Ferrucci L, Penninx BW, Volpato S, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 2002; 50: 1947-54.

23. Freemont AJ, Hoyland JA. Morphology, mechanisms and pathology of musculoskeletal ageing. J Pathol 2007; 211: 252-9.

24. Paolisso G, Gambardella A, Balbi V, et al. Effects of magnesium and nifedipine infusions on insulin action, substrate oxidation, and blood pressure in aged hypertensive patients. Am J Hypertens 1993; 6: 920-6.

25. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.

26. Abbatecola AM, Ferrucci L, Grella R et al. Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc 2004; 52: 399-404.

27. Kawazoe Y, Naka T, Fujimoto M, et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 2001; 193: 263-9.

28. Maggio M, Guralnik JM, Longo DL et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006; 61: 575-84.

29. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113( Pt 16): 2813-9.

30. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119-25.

31. Cappola AR, Xue QL, Ferrucci L et al. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88: 2019-25.